Takeda, Sanofi Partner in Diabetes Education and for a Fixed Dose Combination

Sanofi K.K., the Japanese operations of Sanofi, and Takeda Pharmaceutical Company Limited have partnered to to build a collaborative system within Japan in the field of diabetes awareness and education. By establishing this partnership, the two companies aim to offer more treatment solutions and information to healthcare professionals addressing diversified medical needs of people with diabetes. Through the agreement, the two companies will also be able to expand educational activities regarding the disease.

The collaboration will focus on three areas: raising public awareness of diabetes and educating on how to prevent diabetes, including lifestyle management; providing educational support to patients to emphasize the importance of dietary and exercise therapies and appropriate drug treatment; and providing healthcare professionals with comprehensive information on diabetes care.

The agreement involves no initial payment or other compensation. The manufacturing and marketing rights holder of each company's respective products will conduct its own product promotion and collection and dissemination of product safety information.

In addition to this agreement, both parties have agreed to start formulation development studies of a fixed dose combination of tofogliflozin (product name: Apleway) and alogliptin (product name: Nesina). Tofogliflozin is an orally active small molecule sodium-glucose co-transporter type 2 (SGLT2) inhibitor, developed by Chugai Pharmaceutical for the treatment of Type 2 diabetes mellitus and subsequently licensed by Sanofi K.K. and Kowa. Tofogliflozin received its first global approval for this indication in Japan as either a monotherapy or in combination with other antihyperglcaemic agents. Nesina is a dipeptidyl peptidase-IV (DPP-4) inhibitor for treating Type II diabetes. It was created by Takeda San Diego, Inc., Takeda’s wholly owned subsidiary located in San Diego, California, and received approval by the US Food and Drug Administration in 2013.

Source: Takeda



Leave a Reply

Your email address will not be published. Required fields are marked *